List of Kynamro drug patents
Kynamro is owned by Kastle Theraps Llc.
Kynamro contains Mipomersen Sodium.
Kynamro has a total of 3 drug patents out of which 0 drug patents have expired.
Kynamro was authorised for market use on 29 January, 2013.
Kynamro is available in solution;subcutaneous dosage forms.
The generics of Kynamro are possible to be released after 29 January, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(a month from now) | |
| US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(6 months from now) | |
| US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(3 years from now) | |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
Market Authorisation Date: 29 January, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic